Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information (Tables)

v3.3.0.814
Note 3 - Segment Information (Tables)
 3 Months Ended
Sep. 30, 2015
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
 
September 30,
 
 
 
2015
 
 
2014
 
Net sales
                
Biotechnology
   $ 75,743     $ 76,453  
Clinical Controls
     20,362       19,119  
Protein Platforms
     16,296       12,914  
Inter segment
     (20
)
     (9
)
Consolidated net sales
   $ 112,381     $ 108,477  
Segment operating income
                
Biotechnology
   $ 39,316     $ 40,446  
Clinical Controls
     4,711       6,108  
Protein Platforms
     (1,172
)
     2,604  
Subtotal reportable segments
     42,855       49,159  
Cost recognized on sale of acquired inventory
     (1,112
)
     (3,167
)
Amortization of acquisition related intangible assets
     (7,411
)
     (5,728
)
Acquisition related expenses
     (301
)
     (2,370
)
Stock-based compensation
     (2,038
)
     (1,362
)
Corporate general and administrative
     (965
)
     (1,316
)
Consolidated operating income   $ 31,028     $ 35,216